Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study

Andrea Visentin; Francesca Romana Mauro; Lydia Scarfò; Massimo Gentile; Lucia Farina; Gianluigi Reda; Isacco Ferrarini; Giulia Proietti; Enrico Derenzini; Francesca Cibien; Candida Vitale; Alessandro Sanna; Daniela Pietrasanta; Monia Marchetti; Roberta Murru; Gian Matteo Rigolin; Paolo Sportoletti; Valentina Trimarco; Chiara Adele Cavarretta; Francesco Angotzi; Alessandro Cellini; Valeria Ruocco; Ivan Zatta; Luca Laurenti; Stefano Molica; Marta Coscia; Paolo Ghia; Robin Foà; Antonio Cuneo; Livio Trentin

doi:10.1002/ajh.27009

Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study

Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29.

Authors

Andrea Visentin^{1

2}, Francesca Romana Mauro³, Lydia Scarfò⁴, Massimo Gentile^{5

6}, Lucia Farina⁷, Gianluigi Reda⁸, Isacco Ferrarini⁹, Giulia Proietti³, Enrico Derenzini¹⁰, Francesca Cibien¹¹, Candida Vitale¹², Alessandro Sanna¹³, Daniela Pietrasanta¹⁴, Monia Marchetti¹⁴, Roberta Murru¹⁵, Gian Matteo Rigolin¹⁶, Paolo Sportoletti¹⁷, Valentina Trimarco¹, Chiara Adele Cavarretta¹, Francesco Angotzi¹, Alessandro Cellini¹, Valeria Ruocco¹, Ivan Zatta¹, Luca Laurenti¹⁸, Stefano Molica¹⁹, Marta Coscia¹², Paolo Ghia⁴, Robin Foà³, Antonio Cuneo¹⁶, Livio Trentin^{1

2}

Affiliations

¹ Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy.
² Veneto Institute of Molecular Medicine, Padua, Italy.
³ Hematology, Department of Translational and Precision Medicine, "Sapienza" University, Rome, Italy.
⁴ Strategic Research Program on CLL, Università Vita-salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.
⁵ Hematology Unit, Azienda Ospedaliera of Cosenza, Cosenza, Italy.
⁶ Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
⁷ Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
⁸ Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore, University of Milan, Milan, Italy.
⁹ Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
¹⁰ Divisions of Haemato-oncology, Haematology Programme, European Institute of Oncology IRCCS, Milan, Italy.
¹¹ Hematology Unit, Ca' Foncello Hospital, Treviso, Italy.
¹² Department of Molecular Biotechnology and Health Sciences, University of Torino and Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy.
¹³ Hematology Unit, Department of Oncology, AOU Careggi, Florence, Italy.
¹⁴ Division of Hematology, A.O. SS Antonio e Biagio and Cesare Arrigo, Alessandria, Italy.
¹⁵ Hematology and Stem Cell Transplantation Unit, Ospedale A. Businco, ARNAS G. Brotzu, Cagliari, Italy.
¹⁶ Hematology Section, Department of Medical Sciences, Azienda Ospedaliera-Universitaria, Arcispedale S. Anna, University of Ferrara, Ferrara, Italy.
¹⁷ Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy.
¹⁸ Hematology Institute, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy.
¹⁹ Center of biomedicine, University of Hull, Hull, UK.

PMID: 37382471
DOI: 10.1002/ajh.27009

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
Sulfonamides / therapeutic use
Tumor Suppressor Protein p53 / genetics

Substances

venetoclax
Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
TP53 protein, human
Tumor Suppressor Protein p53